𝔖 Bobbio Scriptorium
✦   LIBER   ✦

No global loss of neocortical neurons in parkinson's disease: A quantitative stereological study

✍ Scribed by Kamilla M. Pedersen; Lisbeth Marner; Henning Pakkenberg; Bente Pakkenberg

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
216 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The global total number of neocortical neurons was estimated in 10 patients with Parkinson's disease (PD; mean age, 74.8 years; range, 68–83) and compared to 12 comparison subjects (mean age, 75.8 years; range, 70 – 84). The total mean neocortical neuron number in the patients with PD was 18.6 × 10^9^ with a coefficient of variation (CV = SD/mean) of 0.18, which was not statistically significantly different from that of the controls (18.8 × 10^9^; CV = 0.16; P = 0.90). In contrast to some studies reporting neocortical atrophy this was not confirmed in our study, where the mean volume of neocortex was the same in the two groups (P = 0.59). No difference was found in the volume of white matter, central gray structures, archicortex, or the ventricular system between the two groups. Most patients with PD develop cognitive disturbances with time, and this study cannot exclude that local neuron loss in specific subpopulations of neocortical neurons or cell loss in small but essential neocortical subregions may be part of the structural defects of PD. © 2004 Movement Disorder Society

📜 SIMILAR VOLUMES

Hippocampal neuron and glial cell number
Hippocampal neuron and glial cell numbers in Parkinson's disease—A stereological study
✍ F.C. Joelving; R. Billeskov; J.R. Christensen; M. West; B. Pakkenberg 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 1 views

Hippocampal atrophy and neuron loss are early and reproducible findings in Alzheimer's disease, and recent magnetic resonance imaging studies indicate that hippocampal atrophy may also be present in Parkinson's disease (PD). To determine whether or not cell loss occurs in PD, we estimated the total

Higher nigrostriatal dopamine neuron los
Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?—A [99mTc]-TRODAT-1 SPECT study
✍ Ming Chi Shih; Luiz Augusto Franco de Andrade; Edson Amaro Jr; Andre Carvalho Fe 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

## Abstract Early‐onset Parkinson's disease (EOPD) is distinct from the classic late‐onset PD (LOPD) because of its slower disease progression. The aim of this study was to compare dopamine neuronal loss in EOPD with that of LOPD with the same disease duration, through dopamine transporter (DAT) es

Quantitative description of loss of clin
Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease
✍ Robert A. Hauser; Nicholas H.G. Holford 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

## Abstract In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient d